Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals has notified the market of the lapse of a series of options and performance rights, resulting in the cessation of several classes of securities. A total of 8,819,840 options and performance rights expired on 19 May 2026 after their vesting or performance conditions were not met or became incapable of being satisfied, slightly simplifying the company’s capital structure and limiting potential future dilution for existing shareholders.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an Australian-listed pharmaceutical company focused on developing and commercialising therapeutics, with its shares traded on the ASX under the code BOT. The company utilises options and performance rights as part of its capital structure and incentive arrangements for executives and employees.
Average Trading Volume: 23,546,410
Technical Sentiment Signal: Sell
Current Market Cap: A$68.1M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.